Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619469 | 0.84 | SMN1; SMN2 (0.54) | GAAKMT2ASMN1; SMN2CTBP2VNN1 | |
| SCHEMBL8962221 | 0.81 | NPC1 (0.43) | KMT2ACTBP2VNN1TDP1ALDH1A1 | |
| SCHEMBL7674308 | 0.81 | GAA (0.47) | GAAKMT2ASMN1; SMN2CTBP2HTT | |
| SCHEMBL24890434 | 0.81 | L3MBTL1 (0.51) | KMT2ASMN1; SMN2CTBP2VNN1TDP1 | |
| SCHEMBL526194 | 0.80 | GAA (0.57) | GAAKMT2ASMN1; SMN2CTBP2HTT | |
| SCHEMBL12731522 | 0.79 | GAA (0.48) | GAAKMT2ASMN1; SMN2CTBP2VNN1 | |
| SCHEMBL8526128 | 0.77 | SLC6A4 (0.41) | KMT2ASMN1; SMN2TDP1ALDH1A1LMNA | |
| SCHEMBL8711809 | 0.77 | FFAR4 (0.45) | KMT2AVNN1ALDH1A1LMNA | |
| SCHEMBL9080910 | 0.77 | MAPK1 (0.36) | KMT2AVNN1HTTALDH1A1EGFR | |
| SCHEMBL28154639 | 0.77 | TAAR1 (0.48) | GAAKMT2ASMN1; SMN2CTBP2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115975178-A | Preparation method of polyaryletherketone resin with alkyl structure in main chain, polyaryletherketone resin with alkyl structure in main chain and application | 中国科学院大连化学物理研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-115975179-A | Preparation method of alkyl structure-containing polyaryletherketone resin, alkyl structure-containing polyaryletherketone resin and application | 中国科学院大连化学物理研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-115975179-A | Preparation method of alkyl structure-containing polyaryletherketone resin, alkyl structure-containing polyaryletherketone resin and application | 中国科学院大连化学物理研究所 | 2023-04-18 | — | — | CN | disclosed |
| CN-115975178-A | Preparation method of polyaryletherketone resin with alkyl structure in main chain, polyaryletherketone resin with alkyl structure in main chain and application | 中国科学院大连化学物理研究所 | 2023-04-18 | — | — | CN | disclosed |
| US-6486194-B2 | ALZHEIMER'S DISEASE | MERCK FROSST CANADA, INC. (CA) | 2002-11-26 | — | — | US | disclosed |
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | MERCK FROSST CANADA INC./MERCK FROSST CANADA & CO. | 2001-08-23 | — | — | US | disclosed |
| US-6239173-B1 | ANTIINFLAMMATORY, ANTIPYRETIC, ANALGESIC, AND ANTIARTHRITIC AGENTS | MERCK FROSST CANADA INC./MERCK FROSST CANADA & CO. (CA) | 2001-05-29 | — | — | US | disclosed |
| EP-0980866-A2 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | Merck Frosst Canada & Co. (CA) | 2000-02-23 | — | — | EP | disclosed |
| US-5840746-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1998-11-24 | — | — | US | disclosed |
| EP-0822190-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1998-02-04 | — | — | EP | disclosed |
| US-5710140-A | ANTIINFLAMMATORY AGENT; ANALGESICS; ANTIPYRETIC AGENT | MERCK FROSST CANADA, INC. (CA) | 1998-01-20 | — | — | US | disclosed |
| EP-0754687-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1997-01-22 | — | — | EP | disclosed |
| EP-0739340-A1 | PHENYL HETEROCYCLES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-10-30 | — | — | EP | disclosed |
| US-5550142-A | CYCLOOXYGENASE INHIBITORS; ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETIC AGENTS | MERCK FROSST CANADA INC. (CA) | 1996-08-27 | — | — | US | disclosed |
| US-5536752-A | TREATMENT OF CYCLOOXYGENASE-2 MEDIATED DISEASES; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA INC. (CA) | 1996-07-16 | — | — | US | disclosed |
| EP-0705254-A1 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-04-10 | — | — | EP | disclosed |
| US-5474995-A | Nonsteroidal, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1995-12-12 | — | — | US | disclosed |
| WO-1995018799-A1 | PHENYL HETEROCYCLES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995000501-A2 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | PTGS1, PTGES2, PTGS2 | GAA 1001/4885KMT2A 3803/4885SMN1; SMN2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.